Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/ MAPK Pathway of Hepatic Stellate Cells
Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammat...
Saved in:
| Published in | Biomolecules & therapeutics Vol. 28; no. 6; pp. 527 - 536 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Society of Applied Pharmacology
01.11.2020
한국응용약물학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1976-9148 2005-4483 |
| DOI | 10.4062/biomolther.2020.016 |
Cover
Loading…
| Abstract | Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammation and apoptosis, leading to liver fibrogenesis through a mitogen-activated protein kinase (MAPK) downstream signals. In this study, we investigated whether selonsertib, a selective inhibitor of ASK1, shows therapeutic efficacy for liver fibrosis, and elucidated its mechanism of action
and
. As a result, selonsertib strongly suppressed the growth and proliferation of hepatic stellate cells (HSCs) and induced apoptosis by increasing Annexin V and TUNEL-positive cells. We also observed that selonsertib inhibited the ASK1/MAPK pathway, including p38 and c-Jun N-terminal kinase (JNK) in HSCs. Interestingly, dimethylnitrosamine (DMN)-induced liver fibrosis was significantly alleviated by selonsertib treatment in rats. Furthermore, selonsertib reduced collagen deposition and the expression of extracellular components such as α-smooth muscle actin (α-SMA), fibronectin, and collagen type I
and
. Taken together, selonsertib suppressed fibrotic response such as HSC proliferation and extracellular matrix components by blocking the ASK1/MAPK pathway. Therefore, we suggest that selonsertib may be an effective therapeutic drug for ameliorating liver fibrosis. |
|---|---|
| AbstractList | Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammation and apoptosis, leading to liver fibrogenesis through a mitogen-activated protein kinase (MAPK) downstream signals. In this study, we investigated whether selonsertib, a selective inhibitor of ASK1, shows therapeutic efficacy for liver fibrosis, and elucidated its mechanism of action
and
. As a result, selonsertib strongly suppressed the growth and proliferation of hepatic stellate cells (HSCs) and induced apoptosis by increasing Annexin V and TUNEL-positive cells. We also observed that selonsertib inhibited the ASK1/MAPK pathway, including p38 and c-Jun N-terminal kinase (JNK) in HSCs. Interestingly, dimethylnitrosamine (DMN)-induced liver fibrosis was significantly alleviated by selonsertib treatment in rats. Furthermore, selonsertib reduced collagen deposition and the expression of extracellular components such as α-smooth muscle actin (α-SMA), fibronectin, and collagen type I
and
. Taken together, selonsertib suppressed fibrotic response such as HSC proliferation and extracellular matrix components by blocking the ASK1/MAPK pathway. Therefore, we suggest that selonsertib may be an effective therapeutic drug for ameliorating liver fibrosis. Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammation and apoptosis, leading to liver fibrogenesis through a mitogen-activated protein kinase (MAPK) downstream signals. In this study, we investigated whether selonsertib, a selective inhibitor of ASK1, shows therapeutic efficacy for liver fibrosis, and elucidated its mechanism of action in vivo and in vitro. As a result, selonsertib strongly suppressed the growth and proliferation of hepatic stellate cells (HSCs) and induced apoptosis by increasing Annexin V and TUNEL-positive cells. We also observed that selonsertib inhibited the ASK1/MAPK pathway, including p38 and c-Jun N-terminal kinase (JNK) in HSCs. Interestingly, dimethylnitrosamine (DMN)-induced liver fibrosis was significantly alleviated by selonsertib treatment in rats. Furthermore, selonsertib reduced collagen deposition and the expression of extracellular components such as α-smooth muscle actin (α-SMA), fibronectin, and collagen type I in vitro and in vivo. Taken together, selonsertib suppressed fibrotic response such as HSC proliferation and extracellular matrix components by blocking the ASK1/MAPK pathway. Therefore, we suggest that selonsertib may be an effective therapeutic drug for ameliorating liver fibrosis. KCI Citation Count: 15 Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammation and apoptosis, leading to liver fibrogenesis through a mitogen-activated protein kinase (MAPK) downstream signals. In this study, we investigated whether selonsertib, a selective inhibitor of ASK1, shows therapeutic efficacy for liver fibrosis, and elucidated its mechanism of action in vivo and in vitro. As a result, selonsertib strongly suppressed the growth and proliferation of hepatic stellate cells (HSCs) and induced apoptosis by increasing Annexin V and TUNEL-positive cells. We also observed that selonsertib inhibited the ASK1/MAPK pathway, including p38 and c-Jun N-terminal kinase (JNK) in HSCs. Interestingly, dimethylnitrosamine (DMN)-induced liver fibrosis was significantly alleviated by selonsertib treatment in rats. Furthermore, selonsertib reduced collagen deposition and the expression of extracellular components such as α-smooth muscle actin (α-SMA), fibronectin, and collagen type I in vitro and in vivo. Taken together, selonsertib suppressed fibrotic response such as HSC proliferation and extracellular matrix components by blocking the ASK1/MAPK pathway. Therefore, we suggest that selonsertib may be an effective therapeutic drug for ameliorating liver fibrosis.Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammation and apoptosis, leading to liver fibrogenesis through a mitogen-activated protein kinase (MAPK) downstream signals. In this study, we investigated whether selonsertib, a selective inhibitor of ASK1, shows therapeutic efficacy for liver fibrosis, and elucidated its mechanism of action in vivo and in vitro. As a result, selonsertib strongly suppressed the growth and proliferation of hepatic stellate cells (HSCs) and induced apoptosis by increasing Annexin V and TUNEL-positive cells. We also observed that selonsertib inhibited the ASK1/MAPK pathway, including p38 and c-Jun N-terminal kinase (JNK) in HSCs. Interestingly, dimethylnitrosamine (DMN)-induced liver fibrosis was significantly alleviated by selonsertib treatment in rats. Furthermore, selonsertib reduced collagen deposition and the expression of extracellular components such as α-smooth muscle actin (α-SMA), fibronectin, and collagen type I in vitro and in vivo. Taken together, selonsertib suppressed fibrotic response such as HSC proliferation and extracellular matrix components by blocking the ASK1/MAPK pathway. Therefore, we suggest that selonsertib may be an effective therapeutic drug for ameliorating liver fibrosis. Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammation and apoptosis, leading to liver fibrogenesis through a mitogen-activated protein kinase (MAPK) downstream signals. In this study, we investigated whether selonsertib, a selective inhibitor of ASK1, shows therapeutic efficacy for liver fibrosis, and elucidated its mechanism of action in vivo and in vitro . As a result, selonsertib strongly suppressed the growth and proliferation of hepatic stellate cells (HSCs) and induced apoptosis by increasing Annexin V and TUNEL-positive cells. We also observed that selonsertib inhibited the ASK1/MAPK pathway, including p38 and c-Jun N-terminal kinase (JNK) in HSCs. Interestingly, dimethylnitrosamine (DMN)-induced liver fibrosis was significantly alleviated by selonsertib treatment in rats. Furthermore, selonsertib reduced collagen deposition and the expression of extracellular components such as α-smooth muscle actin (α-SMA), fibronectin, and collagen type I in vitro and in vivo . Taken together, selonsertib suppressed fibrotic response such as HSC proliferation and extracellular matrix components by blocking the ASK1/MAPK pathway. Therefore, we suggest that selonsertib may be an effective therapeutic drug for ameliorating liver fibrosis. |
| Author | Ryu, Ji-Kan Jung, Kyung Hee Yoon, Young-Chan Hong, Soon-Sun Fang, Zhenghuan Lee, Ji Eun Park, Jung Hee |
| AuthorAffiliation | 2 Department of Urology, College of Medicine, Inha University, Incheon 22332, Republic of Korea 1 Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea |
| AuthorAffiliation_xml | – name: 2 Department of Urology, College of Medicine, Inha University, Incheon 22332, Republic of Korea – name: 1 Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea |
| Author_xml | – sequence: 1 givenname: Young-Chan surname: Yoon fullname: Yoon, Young-Chan organization: Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea – sequence: 2 givenname: Zhenghuan surname: Fang fullname: Fang, Zhenghuan organization: Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea – sequence: 3 givenname: Ji Eun surname: Lee fullname: Lee, Ji Eun organization: Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea – sequence: 4 givenname: Jung Hee surname: Park fullname: Park, Jung Hee organization: Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea – sequence: 5 givenname: Ji-Kan surname: Ryu fullname: Ryu, Ji-Kan organization: Department of Urology, College of Medicine, Inha University, Incheon 22332, Republic of Korea – sequence: 6 givenname: Kyung Hee surname: Jung fullname: Jung, Kyung Hee organization: Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea – sequence: 7 givenname: Soon-Sun surname: Hong fullname: Hong, Soon-Sun organization: Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32451370$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002638303$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kU9vEzEQxS3UiqaFT4CEfIRDUq_t9a4vSFGgNGoQFSlny_bONqabdbCdVP32eJO2_DlwGmn8e29m_E7RUe97QOhNQSacCHpunF_7Lq0gTCihZEIK8QKNKCHlmPOaHaFRISsxlgWvT9BpjD8IEVVRipfohFFeFqwiI9QuofN9hJCcwfN-5YxLES_cDgK-cCb46CLeOY0_-vs-wO2208n5HvsWT5dXxTn-Mr2-wtc6re71w9C9hE0mLF4m6DILeJZrfIWOW91FeP1Yz9D3i083s8vx4uvn-Wy6GFvOZBq3FoihLUgjhTWkAaYbqKtaV6wRpOBlQwjL7ZoBYaahRJSWa17le2wtjGRn6P3Btw-turNOee329daru6Cm327mSpaSciEy--HAbrZmDY2FPgXdqU1wax0e9sq_X3q3yj47VZV1KTjJBu8eDYL_uYWY1NpFO5zdg99GRXNMsqS0GtC3f856HvIURAbYAbD5y2OA9hkpiBriVr_jVkPcKsedVfIflXVpH1Be2HX_1f4CDhK0iw |
| CitedBy_id | crossref_primary_10_3389_fphar_2021_687033 crossref_primary_10_1016_j_phymed_2023_154721 crossref_primary_10_1002_jbt_23338 crossref_primary_10_1016_j_ejphar_2023_176270 crossref_primary_10_1111_jgh_16087 crossref_primary_10_1016_j_ejmech_2022_115057 crossref_primary_10_1097_HEP_0000000000000893 crossref_primary_10_1016_j_drudis_2021_12_012 crossref_primary_10_1038_s12276_022_00883_0 crossref_primary_10_3389_fmolb_2022_835508 crossref_primary_10_1007_s12272_022_01404_3 crossref_primary_10_1002_mco2_721 crossref_primary_10_3390_ijtm5010007 crossref_primary_10_1016_j_molmet_2021_101190 crossref_primary_10_1007_s11033_022_07783_6 crossref_primary_10_1038_s41598_024_55438_2 crossref_primary_10_4062_biomolther_2022_108 crossref_primary_10_1016_j_jep_2022_115960 crossref_primary_10_3390_cells10102759 crossref_primary_10_3389_fcell_2021_730176 crossref_primary_10_1016_j_isci_2021_103549 crossref_primary_10_3389_jpps_2023_11808 crossref_primary_10_7759_cureus_69129 crossref_primary_10_1096_fj_202401676RR crossref_primary_10_3390_ijms24119671 crossref_primary_10_1007_s11011_022_01061_x crossref_primary_10_1038_s41392_022_01119_3 crossref_primary_10_1038_s41598_021_01951_7 crossref_primary_10_1165_rcmb_2021_0465OC crossref_primary_10_3389_fonc_2022_865454 crossref_primary_10_1039_D3TB02790B crossref_primary_10_1016_j_intimp_2022_109563 |
| Cites_doi | 10.1053/gast.2002.32995 10.1007/s12072-018-9854-1 10.1172/JCI24282 10.2183/pjab.88.434 10.1016/j.bbamcr.2007.03.010 10.1002/cbin.10790 10.1139/bcb-2014-0036 10.1002/hep.29514 10.1038/emm.2013.134 10.1074/jbc.M003412200 10.1111/j.1872-034X.2008.00394.x 10.1016/j.biomaterials.2010.10.023 10.1126/science.275.5296.90 10.1172/JCI99768 10.1016/j.jhep.2010.02.027 10.14218/JCTH.2013.00005 10.1053/j.gastro.2009.09.015 10.1093/embo-reports/kve046 10.3390/ijms20061358 10.1016/j.addr.2017.05.007 10.1002/hep.23186 10.1164/rccm.201703-0502OC 10.1016/j.dld.2004.11.009 10.1089/ars.2013.5697 10.1111/jcmm.13705 10.1053/j.gastro.2008.07.006 10.1111/apt.13620 10.1038/nri3623 10.1159/000495390 10.3748/wjg.v24.i25.2661 10.3748/wjg.v22.i48.10512 10.1074/jbc.M409381200 10.1007/s10495-005-1055-4 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020, The Korean Society of Applied Pharmacology 2020 |
| Copyright_xml | – notice: Copyright © 2020, The Korean Society of Applied Pharmacology 2020 |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.4062/biomolther.2020.016 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2005-4483 |
| EndPage | 536 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9592466 PMC7585640 32451370 10_4062_biomolther_2020_016 |
| Genre | Journal Article |
| GroupedDBID | --- 23N 5-W 5GY 8JR 9ZL AAYXX ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. F5P HYE HZB JDI KQ8 M48 OK1 PGMZT RPM .UV NPM 7X8 5PM ACYCR ADRAZ |
| ID | FETCH-LOGICAL-c439t-fce0b2fe9b96cb0de3ade878a73d60145d0030de83e03bd2065c4a47324c86b93 |
| IEDL.DBID | M48 |
| ISSN | 1976-9148 |
| IngestDate | Tue Nov 21 21:32:29 EST 2023 Thu Aug 21 13:20:39 EDT 2025 Fri Jul 11 10:51:29 EDT 2025 Thu Jan 02 22:58:33 EST 2025 Tue Jul 01 04:15:29 EDT 2025 Thu Apr 24 23:02:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Liver fibrosis MAPK ASK1 Selonsertib |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c439t-fce0b2fe9b96cb0de3ade878a73d60145d0030de83e03bd2065c4a47324c86b93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2020.016 |
| PMID | 32451370 |
| PQID | 2406952270 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9592466 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7585640 proquest_miscellaneous_2406952270 pubmed_primary_32451370 crossref_primary_10_4062_biomolther_2020_016 crossref_citationtrail_10_4062_biomolther_2020_016 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-11-01 |
| PublicationDateYYYYMMDD | 2020-11-01 |
| PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Biomolecules & therapeutics |
| PublicationTitleAlternate | Biomol Ther (Seoul) |
| PublicationYear | 2020 |
| Publisher | The Korean Society of Applied Pharmacology 한국응용약물학회 |
| Publisher_xml | – name: The Korean Society of Applied Pharmacology – name: 한국응용약물학회 |
| References | ref13 ref12 ref15 ref14 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – ident: ref14 doi: 10.1053/gast.2002.32995 – ident: ref18 doi: 10.1007/s12072-018-9854-1 – ident: ref4 doi: 10.1172/JCI24282 – ident: ref11 doi: 10.2183/pjab.88.434 – ident: ref7 doi: 10.1016/j.bbamcr.2007.03.010 – ident: ref8 doi: 10.1002/cbin.10790 – ident: ref31 doi: 10.1139/bcb-2014-0036 – ident: ref21 doi: 10.1002/hep.29514 – ident: ref27 doi: 10.1038/emm.2013.134 – ident: ref10 doi: 10.1074/jbc.M003412200 – ident: ref25 doi: 10.1111/j.1872-034X.2008.00394.x – ident: ref19 doi: 10.1016/j.biomaterials.2010.10.023 – ident: ref13 doi: 10.1126/science.275.5296.90 – ident: ref20 doi: 10.1172/JCI99768 – ident: ref30 doi: 10.1016/j.jhep.2010.02.027 – ident: ref3 doi: 10.14218/JCTH.2013.00005 – ident: ref17 doi: 10.1053/j.gastro.2009.09.015 – ident: ref28 doi: 10.1093/embo-reports/kve046 – ident: ref15 doi: 10.3390/ijms20061358 – ident: ref12 doi: 10.1016/j.addr.2017.05.007 – ident: ref26 doi: 10.1002/hep.23186 – ident: ref5 doi: 10.1164/rccm.201703-0502OC – ident: ref6 doi: 10.1016/j.dld.2004.11.009 – ident: ref2 doi: 10.1089/ars.2013.5697 – ident: ref1 doi: 10.1111/jcmm.13705 – ident: ref22 doi: 10.1053/j.gastro.2008.07.006 – ident: ref23 doi: 10.1111/apt.13620 – ident: ref24 doi: 10.1038/nri3623 – ident: ref33 doi: 10.1159/000495390 – ident: ref16 doi: 10.3748/wjg.v24.i25.2661 – ident: ref32 doi: 10.3748/wjg.v22.i48.10512 – ident: ref29 doi: 10.1074/jbc.M409381200 – ident: ref9 doi: 10.1007/s10495-005-1055-4 |
| SSID | ssj0067156 |
| Score | 2.3568575 |
| Snippet | Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 527 |
| SubjectTerms | Original 약학 |
| Title | Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/ MAPK Pathway of Hepatic Stellate Cells |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32451370 https://www.proquest.com/docview/2406952270 https://pubmed.ncbi.nlm.nih.gov/PMC7585640 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002638303 |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biomolecules & Therapeutics, 2020, 28(6), , pp.527-536 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED4BkyZepqH96jaQN-1xKUmc2skTqoCqjDEhdZV4s2zHhogq2ZKyjf-eu6QtP8T2sKdIju0o_uzc98XnO4BPXGQ2C7UJpMs4CpQBD4z1EWqePPeRcB5vk7fFNzGeJl_OBmdrsMyKuhjA5lFpR_mkpvWs_-fn9R4ueOSvfTRH8S4dVK9mxJdQ78VhH1nMOjxB0yRomp8kq20FIaM2nWuENhhXeZJ2YYj-1skmPEW6MYg4ZTK-Y7XWy9o_Rkgf-lXeMVSj5_BswTDZsJsSW7DmyhfgJm5GftNYaNhReVGYYt6wr-SUwUaomKumaNivQrMDVOV1l58eEWOVZ8PJcbR7Mjw9ZqfIFn_rayocO_LEtmxCh1CQrrJ9vDYvYTo6_L4_DhYZFgKLRGQeeOtCE3uXmUxYE-aO69ylMtWS54I2HHP6CGARdyE3eYx8xSY6kTgsNhUm469go6xK9wYYlza3KXYmUp9ok2gnjIhNmGZCeyN9D-LlCCq7CD9OWTBmCmUIIaBuEVCEgEIEevB51ehHF33j39U_IjTq0haKombT9bxSl7VCbXCksgFqTYGVPiyRU7iUaH9El666alR7Chj5qAx78LpDcvXU5UTogbyH8aoCPfD-nbK4aMN1kyITSfj2v1u-g016w-4E5HvYmNdXbhup0NzstNN7p_1HdQPkNw0A |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selonsertib+Inhibits+Liver+Fibrosis+via+Downregulation+of+ASK1%2FMAPK+Pathway+of+Hepatic+Stellate+Cells&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Yoon%2C+Young-Chan&rft.au=Fang%2C+Zhenghuan&rft.au=Lee%2C+Ji+Eun&rft.au=Park%2C+Jung+Hee&rft.date=2020-11-01&rft.pub=The+Korean+Society+of+Applied+Pharmacology&rft.issn=1976-9148&rft.eissn=2005-4483&rft.volume=28&rft.issue=6&rft.spage=527&rft.epage=536&rft_id=info:doi/10.4062%2Fbiomolther.2020.016&rft_id=info%3Apmid%2F32451370&rft.externalDocID=PMC7585640 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-9148&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-9148&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-9148&client=summon |